BTK inhibitors
Bruton's tyrosine kinase (BTK) inhibitors are a class of pharmaceutical agents that target and inhibit the activity of BTK, a key enzyme involved in B-cell receptor signaling pathways. BTK plays a crucial role in the development, activation, and survival of B-cells by transmitting signals from various cell surface receptors, including the B-cell receptor (BCR), cytokine receptors, and Toll-like receptors. Inhibiting BTK disrupts these signaling pathways, leading to impaired B-cell proliferation, survival, and antibody production. This makes BTK inhibitors particularly effective in treating B-cell malignancies, such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and other B-cell-related disorders. Additionally, BTK inhibitors have shown promise in autoimmune diseases, where aberrant B-cell activation contributes to disease pathology.
- Structure
- Product name
- CAS No.
- Molecular formula
- Inquiry
Total:4 Page 1 of 1 1
![N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(tert-butyl)benzamide](http://file1.lookchem.com/300w/synthetic/2022-01-23-01/b30ba850-0dc0-4bac-8e17-7028232aee0d.png)